¼¼°èÀÇ ÀçÅà ¼¿ÇÁ ¸ð´ÏÅ͸µ ±â±â ½ÃÀå
Homecare Self-Monitoring Devices
»óǰÄÚµå : 1744739
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 393 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,136,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,408,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ÀçÅà ¼¿ÇÁ ¸ð´ÏÅ͸µ ±â±â ¼¼°è ½ÃÀåÀº 2030³â±îÁö 76¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 62¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ÀçÅà ¼¿ÇÁ ¸ð´ÏÅ͸µ ±â±â ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 3.6%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 76¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ Ç÷¾Ð ¸ð´ÏÅÍ´Â CAGR 2.4%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 21¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Ç÷´çÄ¡ ¸ð´ÏÅÍ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 4.7%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 17¾ï ´Þ·¯, Áß±¹Àº CAGR 6.5%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÀçÅà ¼¿ÇÁ ¸ð´ÏÅ͸µ ±â±â ½ÃÀåÀº 2024³â¿¡ 17¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 15¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 6.5%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 1.5%¿Í 2.8%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ÀçÅà ¼¿ÇÁ ¸ð´ÏÅ͸µ ±â±â ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ÀçÅà ¼¿ÇÁ ¸ð´ÏÅ͸µ ±â±â°¡ ¸¸¼ºÁúȯ °ü¸®¸¦ º¯È­½ÃŰ´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

ȨÄɾî¿ë ¼¿ÇÁ ¸ð´ÏÅ͸µ ±â±â´Â º´¿ø Á᫐ ¸ðµ¨¿¡¼­ ȯÀÚ Áß½ÉÀÇ ÀçÅÃÀÇ·á·Î ÀüȯÇÏ´Â µ¥ ÀÖ¾î ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀåÄ¡´Â °³ÀÎÀÌ Ç÷¾Ð, Ç÷´ç, »ê¼ÒÆ÷È­µµ, ½ÉÀüµµ, ü¿Â, üÁß°ú °°Àº Áß¿äÇÑ °Ç°­ ¸Å°³º¯¼ö¸¦ ÃßÀûÇÏ¿© Á¶±â ¹ß°ß, ½Ç½Ã°£ ¸ð´ÏÅ͸µ ¹× Àû½Ã¿¡ °³ÀÔÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. °íÇ÷¾Ð, ´ç´¢º´, ½ÉÇ÷°üÁúȯ, È£Èí±âÁúȯ°ú °°Àº ¸¸¼ºÁúȯÀÌ Àü ¼¼°èÀûÀ¸·Î Áö¼ÓÀûÀ¸·Î Áõ°¡Çϰí ÀÖ´Â »óȲ¿¡¼­, ÀÌ·¯ÇÑ µµ±¸´Â Áö¼ÓÀûÀÎ Áø·á ¾øÀ̵µ Àå±âÀûÀÎ °Ç°­ °ü¸®¸¦ ÇÒ ¼ö ÀÖ´Â ÇʼöÀûÀÎ µµ±¸°¡ µÇ°í ÀÖ½À´Ï´Ù.

µðÁöÅÐ Çコ, ¼ÒÇü ÀüÀÚ±â±â, ¸ð¹ÙÀÏ ¿¬°áÀÇ À¶ÇÕÀº Á¤È®ÇÏ°í »ç¿ëÇϱ⠽¬¿ì¸ç ÈÞ´ë °¡´ÉÇÑ ¸ð´ÏÅ͸µ ¼Ö·ç¼ÇÀ» ÅëÇØ ȯÀÚ°¡ ÀÚ½ÅÀÇ °Ç°­À» °ü¸®ÇÒ ¼ö ÀÖ´Â ±ÇÇÑÀ» ºÎ¿©Çϰí ÀÖ½À´Ï´Ù. ƯÈ÷ ½ÅÈï °æÁ¦±¹¿¡¼­´Â Àα¸ °í·ÉÈ­·Î ÀÎÇØ ÀüÀÚ ÀÇ·á ±â·Ï(EHR) ¹× ¿ø°ÝÀÇ·á Ç÷§Æû°ú ÅëÇÕÇÒ ¼ö ÀÖ´Â ÀçÅà °Ç°­ ÃßÀû ±â±â¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µµ±¸´Â ȯÀÚµéÀÇ ¼øÀÀµµ¿Í ÀÚ±â ÀνÄÀ» Çâ»ó½Ãų »Ó¸¸ ¾Æ´Ï¶ó º´¿ø ÀçÀÔ¿øÀ²À» ³·Ãß°í, °¡Ä¡ ±â¹Ý Áø·á¿¡ ÁßÁ¡À» µÎ´Â ȯÀÚ¿Í ÀÇ·á ½Ã½ºÅÛ ¸ðµÎ¿¡ ¸Å¿ì À¯¿ëÇÕ´Ï´Ù.

±â¼ú°ú Ä¿³ØÆ¼ºñƼÀÇ Çõ½ÅÀº Áø´ÜÀÇ Á¤È®¼º°ú Á¢±Ù¼ºÀ» ¾î¶»°Ô Çâ»ó½Ã۰í Àִ°¡?

¹ÙÀÌ¿À¼¾¼­ ±â¼ú, ¹«¼± Åë½Å, Ŭ¶ó¿ìµå ±â¹Ý ºÐ¼®ÀÇ ¹ßÀüÀº ÀçÅà ¼¿ÇÁ ¸ð´ÏÅ͸µ ±â±âÀÇ ±â´É°ú Á¤È®¼ºÀ» ȹ±âÀûÀ¸·Î Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. Áö¼ÓÀû Ç÷´ç ÃøÁ¤±â(CGM), ¿þ¾î·¯ºí ECG ÆÐÄ¡, Ä¿ÇÁ½º ¾ø´Â Ç÷¾Ð ¸ð´ÏÅÍ´Â ÀÇ·á ¼öÁØÀÇ Á¤È®µµ·Î ½Ç½Ã°£ ºñħ½ÀÀû ÃßÀû ±â´ÉÀ» Á¦°øÇϸç, ºí·çÅõ½º ¹× Wi-Fi¸¦ Áö¿øÇÏ´Â ±â±â´Â ¸ð¹ÙÀÏ ¾Û ¹× ÀÇ·á ¼­ºñ½º Á¦°øÀÚÀÇ ´ë½Ãº¸µå¿Í µ¥ÀÌÅ͸¦ ÀÚµ¿À¸·Î µ¿±âÈ­ÇÏ¿© µ¿±âÈ­ÇÏ¿© µ¿Ç⠺м®, °æ°í, ÀÓ»óÀÇÀÇ ¿ø°Ý °ËÅ並 °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù.

ÀΰøÁö´É(AI)Àº °Ç°­¿¡ ´ëÇÑ ÀλçÀÌÆ®¸¦ °³ÀÎÈ­Çϰí, ÀÌ»ó ¡Èĸ¦ °¨ÁöÇϰí, ½ÇÇà °¡´ÉÇÑ °³ÀÔÀ» ±ÇÀåÇϱâ À§ÇØ ³»ÀåµÇ¾î ÀÖ½À´Ï´Ù. À½¼º ¾È³», ÅÍÄ¡½ºÅ©¸° ÀÎÅÍÆäÀ̽º, ´Ù±¹¾î Áö¿ø µîÀÇ ±â´ÉÀ» ÅëÇØ µð¹ÙÀ̽º´Â ´õ¿í Á÷°üÀûÀ¸·Î º¯Çϰí ÀÖÀ¸¸ç, °í·ÉÀÚ³ª ¹®ÇØ·ÂÀÌ ³·Àº »ç¶÷µéÀ» Æ÷ÇÔÇÑ ´õ ¸¹Àº »ç¿ëÀÚÃþÀÌ ½±°Ô »ç¿ëÇÒ ¼ö ÀÖµµ·Ï Çϰí ÀÖ½À´Ï´Ù. ¹èÅ͸® ¼ö¸í °³¼±, ÃæÀü½Ä µðÀÚÀÎ, ¹«¼± ÃæÀüµµ »ç¿ë ÆíÀǼº°ú Àå±âÀûÀÎ ¾ÈÁ¤¼ºÀ» Çâ»ó½ÃÄ×½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀ¸·Î ÀÎÇØ ÀçÅà °Ç°­ °ü¸®´Â È®Àå °¡´ÉÇÑ ¿¹¹æ Ä¡·áÀÇ ÁÖ·ù ¸ðµ¨·Î ÀÚ¸® Àâ¾Æ°¡°í ÀÖ½À´Ï´Ù.

ȯÀÚ Áý´Ü°ú ÇコÄÉ¾î »ýŰ迡¼­ º¸±ÞÀÌ ÁøÇàµÇ°í ÀÖ´Â °÷Àº ¾îµðÀΰ¡?

´ç´¢º´, ½ÉºÎÀü, COPD, °íÇ÷¾Ð µî ¸¸¼ºÁúȯÀ» °ü¸®Çϰí Á¤±âÀûÀÎ ¸Å°³º¯¼ö ¸ð´ÏÅ͸µÀÌ Áß¿äÇÑ È¯ÀÚ¿¡¼­ °¡Àå ¸¹ÀÌ Ã¤Åõǰí ÀÖ½À´Ï´Ù. °í·ÉÀÚ »ç¿ëÀÚ´Â ³ëÈ­ °ü·Ã ÁúȯÀÇ À¯º´·üÀÌ ³ô°í ÀçÅà ġ·á¸¦ ¼±È£Çϱ⠶§¹®¿¡ Áõ°¡ Ãß¼¼¿¡ ÀÖ½À´Ï´Ù. °£º´Àΰú °¡Á·µµ ÁÖ¿ä »ç¿ëÀÚ ±×·ìÀ¸·Î, ƯÈ÷ Àü¹®ÀûÀÎ Ä¡·á°¡ Á¦ÇÑÀûÀÎ °æ¿ì »ç¶ûÇÏ´Â »ç¶÷À» ¿ø°ÝÀ¸·Î ¸ð´ÏÅ͸µÇϱâ À§ÇØ ÀÌ·¯ÇÑ ±â±â¿¡ ÀÇÁ¸ÇÏ´Â °æ¿ì°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

ÀÇ·á ¼­ºñ½º Á¦°øÀÚ, º¸Çè»ç ¹× Á¤ºÎ ±â°üÀº °á°ú¸¦ °³¼±Çϰí Àå±âÀûÀÎ ºñ¿ëÀ» Àý°¨Çϱâ À§ÇØ ÀÌ·¯ÇÑ µµ±¸¸¦ Áø·á Á¶Á¤ Àü·«¿¡ ÅëÇÕÇϰí ÀÖ½À´Ï´Ù. ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ(RPM) ÇÁ·Î±×·¥Àº ¹Î°£ ¹× °ø°ø ºÎ¹® ¸ðµÎ¿¡¼­ ºü¸£°Ô È®´ëµÇ°í ÀÖÀ¸¸ç, FDA ½ÂÀÎ ¹× CE ¸¶Å©°¡ ºÎÂøµÈ ±â±â¿¡ ´ëÇÑ È¯±ÞÀ» ÅëÇØ À¯ÅëÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¸ð¹ÙÀÏ ¿ì¼± Àü·«°ú ºÐ»êÇü ÇコÄÉ¾î ¸ðµ¨ÀÌ Á¢±Ù¼º °ÝÂ÷¸¦ ÇØ¼ÒÇϰí ÀÖ´Â ½ÅÈï ½ÃÀå¿¡¼­µµ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ȨÄÉ¾î ±â±â°¡ ±¤¹üÀ§ÇÑ ¿ø°ÝÀÇ·á ¹× µðÁöÅÐ Ä¡·á »ýŰ迡 ÅëÇյǸ鼭 Çö´ëÀû ÀÇ·á ¼­ºñ½º Á¦°ø¿¡ ÀÖ¾î ȨÄÉ¾î ±â±âÀÇ ¿ªÇÒÀÌ ´õ¿í °­È­µÇ°í ÀÖ½À´Ï´Ù.

ÀçÅà ¼¿ÇÁ ¸ð´ÏÅ͸µ ±â±â ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁý´Ï´Ù...

¸¸¼ºÁúȯÀÇ Áõ°¡, °í·ÉÈ­, ȨÄÉ¾î ¸ðµ¨·ÎÀÇ ±¤¹üÀ§ÇÑ ÀüȯÀÌ ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á¿ë ¼¾¼­ÀÇ °¡°Ý Ç϶ô°ú ¼ÒÇüÈ­ ´öºÐ¿¡ ÀÇ·á¿ë ¼¾¼­°¡ ÀÏ»ó »ýȰ¿¡ ´õ¿í Ä£¼÷ÇÏ°í Æí¾ÈÇÏ°Ô »ç¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. µ¿½Ã¿¡, ÁÖ¿ä ½ÃÀå¿¡¼­ÀÇ »óȯ Á¤Ã¥ ¹× RPM û±¸ ÄÚµåÀÇ È®´ë´Â ȯÀÚ¿Í ÀÇ·á ¼­ºñ½º Á¦°øÀÚ ¸ðµÎ¿¡°Ô ¿ø°Ý ¸ð´ÏÅ͸µ ±â¼úÀÇ µµÀÔÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

½º¸¶Æ®Æù, Ŭ¶ó¿ìµå Ç÷§Æû, ¿þ¾î·¯ºí ¿¡ÄڽýºÅÛ°úÀÇ ÅëÇÕÀ» ÅëÇØ ½Ç½Ã°£ °Ç°­ µ¥ÀÌÅÍ ÃßÀû°ú Àû±ØÀûÀÎ °³ÀÔÀÌ °¡´ÉÇØÁ® Ä¡·á ºñ¿ëÀ» ÁÙÀ̸鼭 Ä¡·á °á°ú¸¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¹«¼± Åë½Å, AI ±â¹Ý ºÐ¼®, µðÁöÅÐ Ä¡·áÇÐÀÇ ¹ßÀüÀº ¿¹ÃøÀûÀÌ°í °³ÀÎÈ­µÈ ÀçÅÃÀǷḦ Áö¿øÇÏ´Â °ß°íÇÑ »ýŰ踦 ±¸ÃàÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, COVID-19¿Í °°Àº ¼¼°è º¸°Ç À§±â´Â ¼¿ÇÁ ¸ð´ÏÅ͸µÀÇ ÀÏ»óÈ­¸¦ °¡¼ÓÈ­Çϰí, °¨¿° ¹× ¸¸¼ºÁúȯ °ü¸®¿¡¼­ ¼¿ÇÁ ¸ð´ÏÅ͸µÀÇ ¿ªÇÒÀ» °­Á¶Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÇÕÀûÀÎ ÈûÀº ÀçÅà ¿ä¾ç¿ë ¼¿ÇÁ ¸ð´ÏÅ͸µ ±â±â ½ÃÀåÀÇ Áö¼ÓÀûÀÎ ¼ºÀå°ú ±â¼úÀû ÁøÈ­¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

À¯Çü(Ç÷¾Ð ¸ð´ÏÅÍ, Ç÷´çÄ¡ ¸ð´ÏÅÍ, SPO2 ¸ð´ÏÅ͸µ ŰƮ, ½ÉÀüµµ Àåºñ, ¼ö¸é °Ë»ç Àåºñ, ±âŸ À¯Çü), µð¹ÙÀ̽º À¯Çü(¿þ¾î·¯ºí, ÇÚµåÇïµå, ±âŸ µð¹ÙÀ̽º À¯Çü), ¿ëµµ(´ë»çÁúȯ, ¼øÈ¯±âÁúȯ, È£Èí±âÁúȯ, ±âŸ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê(ÃÑ 48°³»ç)

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ÀÎÀ§ÀûÀÎ ¸ÅÃâ¿ø°¡ Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Global Industry Analysts´Â ¼¼°è ÁÖ¿ä ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®(1,4,949¸í), ½ÌÅ©ÅÊÅ©(62°³ ±â°ü), ¹«¿ª ¹× »ê¾÷ ´Üü(171°³ ±â°ü)ÀÇ Àü¹®°¡µéÀÇ ÀǰßÀ» ¸é¹ÐÈ÷ °ËÅäÇÏ¿© »ýŰ迡 ¹ÌÄ¡´Â ¿µÇâÀ» Æò°¡ÇÏ°í »õ·Î¿î ½ÃÀå Çö½Ç¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ¸ðµç ÁÖ¿ä ±¹°¡ÀÇ Àü¹®°¡¿Í °æÁ¦ÇÐÀÚµéÀÌ °ü¼¼¿Í ±×°ÍÀÌ ÀÚ±¹¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀǰßÀ» ÃßÀû Á¶»çÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀÌ·¯ÇÑ È¥¶õÀÌ ÇâÈÄ 2-3°³¿ù ³»¿¡ ¸¶¹«¸®µÇ°í »õ·Î¿î ¼¼°è Áú¼­°¡ º¸´Ù ¸íÈ®ÇÏ°Ô È®¸³µÉ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖÀ¸¸ç, Global Industry Analysts´Â ÀÌ·¯ÇÑ »óȲÀ» ½Ç½Ã°£À¸·Î ÃßÀûÇϰí ÀÖ½À´Ï´Ù.

2025³â 4¿ù : Çù»ó ´Ü°è

À̹ø 4¿ù º¸°í¼­¿¡¼­´Â °ü¼¼°¡ ¼¼°è ½ÃÀå Àüü¿¡ ¹ÌÄ¡´Â ¿µÇâ°ú Áö¿ªº° ½ÃÀå Á¶Á¤¿¡ ´ëÇØ ¼Ò°³ÇÕ´Ï´Ù. ´ç»çÀÇ ¿¹ÃøÀº °ú°Å µ¥ÀÌÅÍ¿Í ÁøÈ­ÇÏ´Â ½ÃÀå ¿µÇâ¿äÀÎÀ» ±â¹ÝÀ¸·Î ÇÕ´Ï´Ù.

2025³â 7¿ù : ÃÖÁ¾ °ü¼¼ Àç¼³Á¤

°í°´´Ôµé²²´Â °¢ ±¹°¡º° ÃÖÁ¾ ¸®¼ÂÀÌ ¹ßÇ¥µÈ ÈÄ 7¿ù¿¡ ¹«·á ¾÷µ¥ÀÌÆ® ¹öÀüÀ» Á¦°øÇØ µå¸³´Ï´Ù. ÃÖÁ¾ ¾÷µ¥ÀÌÆ® ¹öÀü¿¡´Â ¸íÈ®ÇÏ°Ô Á¤ÀÇµÈ °ü¼¼ ¿µÇ⠺м®ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

»óÈ£ ¹× ¾çÀÚ °£ ¹«¿ª°ú °ü¼¼ÀÇ ¿µÇ⠺м®:

¹Ì±¹ <> Áß±¹ <> ¸ß½ÃÄÚ <> ij³ª´Ù <> EU <> ÀϺ» <> Àεµ <> ±âŸ 176°³±¹

¾÷°è ÃÖ°íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ® : Global Industry AnalystsÀÇ Áö½Ä ±â¹ÝÀº ±¹°¡, ½ÌÅ©ÅÊÅ©, ¹«¿ª ¹× »ê¾÷ ´Üü, ´ë±â¾÷, ±×¸®°í ¼¼°è °è·® °æÁ¦ »óȲÀÇ Àü·Ê ¾ø´Â ÆÐ·¯´ÙÀÓ ÀüȯÀÇ ¿µÇâÀ» °øÀ¯ÇÏ´Â ºÐ¾ßº° Àü¹®°¡ µî °¡Àå ¿µÇâ·Â ÀÖ´Â ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ® ±×·ìÀ» Æ÷ÇÔÇÑ 14,949¸íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ ÃßÀûÇϰí ÀÖ½À´Ï´Ù. 16,491°³ ÀÌ»óÀÇ º¸°í¼­ ´ëºÎºÐ¿¡ ¸¶ÀϽºÅæ¿¡ ±â¹ÝÇÑ 2´Ü°è Ãâ½Ã ÀÏÁ¤ÀÌ Àû¿ëµÇ¾î ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Homecare Self-Monitoring Devices Market to Reach US$7.6 Billion by 2030

The global market for Homecare Self-Monitoring Devices estimated at US$6.2 Billion in the year 2024, is expected to reach US$7.6 Billion by 2030, growing at a CAGR of 3.6% over the analysis period 2024-2030. Blood Pressure Monitors, one of the segments analyzed in the report, is expected to record a 2.4% CAGR and reach US$2.1 Billion by the end of the analysis period. Growth in the Blood Glucose Monitors segment is estimated at 4.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.7 Billion While China is Forecast to Grow at 6.5% CAGR

The Homecare Self-Monitoring Devices market in the U.S. is estimated at US$1.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.5 Billion by the year 2030 trailing a CAGR of 6.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Global Homecare Self-Monitoring Devices Market - Key Trends & Drivers Summarized

Why Are Homecare Self-Monitoring Devices Transforming Chronic Disease Management?

Homecare self-monitoring devices are playing a pivotal role in shifting healthcare from hospital-centric models to patient-centered care at home. These devices enable individuals to track vital health parameters such as blood pressure, blood glucose, oxygen saturation, ECG, temperature, and weight-allowing for early detection, real-time monitoring, and timely intervention. As chronic diseases such as hypertension, diabetes, cardiovascular disorders, and respiratory conditions continue to rise globally, these tools are becoming essential for managing long-term health without constant clinical visits.

The convergence of digital health, miniaturized electronics, and mobile connectivity is empowering patients to take control of their care through accurate, user-friendly, and portable monitoring solutions. Aging populations, especially in developed economies, are driving demand for at-home health tracking devices that can integrate with electronic health records (EHRs) and telemedicine platforms. These tools not only improve compliance and self-awareness but also reduce hospital readmission rates, making them invaluable to both patients and health systems focused on value-based care.

How Are Innovations in Technology and Connectivity Improving Diagnostic Accuracy and Accessibility?

Advancements in biosensor technology, wireless communication, and cloud-based analytics are drastically enhancing the functionality and precision of homecare self-monitoring devices. Continuous glucose monitors (CGMs), wearable ECG patches, and cuffless blood pressure monitors now offer real-time, non-invasive tracking with medical-grade accuracy. Bluetooth and Wi-Fi-enabled devices automatically sync data with mobile apps or provider dashboards, enabling trend analysis, alerts, and remote clinician review.

Artificial Intelligence (AI) is being incorporated to personalize health insights, detect anomalies, and recommend actionable interventions. Devices are becoming more intuitive, with features like voice prompts, touchscreen interfaces, and multilingual support, making them accessible to a broader user base, including the elderly and low-literacy populations. Battery life improvements, rechargeable designs, and wireless charging are also enhancing ease of use and long-term reliability. These innovations are turning home-based health tracking into a scalable, mainstream model of preventive care.

Where Is Adoption Rising Across Patient Populations and Healthcare Ecosystems?

Adoption is highest among patients managing chronic illnesses such as diabetes, heart failure, COPD, and hypertension, where regular parameter monitoring is critical. Elderly users represent a growing demographic due to the high prevalence of age-related conditions and preference for home-based care. Caregivers and family members are also key user groups, increasingly relying on these devices to monitor loved ones remotely, especially when professional care is limited.

Healthcare providers, insurers, and government agencies are integrating these tools into care coordination strategies to improve outcomes and reduce long-term costs. Remote patient monitoring (RPM) programs are rapidly expanding in both private and public sectors, enabling reimbursement-backed distribution of FDA-cleared and CE-marked devices. Demand is also rising in emerging markets, where mobile-first strategies and decentralized healthcare models are bridging access gaps. The integration of homecare devices into broader telehealth and digital therapeutics ecosystems is further cementing their role in modern care delivery.

The Growth in the Homecare Self-Monitoring Devices Market Is Driven by Several Factors…

It is primarily driven by the global rise in chronic diseases, the aging population, and a broader shift toward home-based care models. The increasing affordability and miniaturization of medical-grade sensors are making devices more accessible and comfortable for everyday use. At the same time, the expansion of reimbursement policies and RPM billing codes in key markets is incentivizing both patients and providers to adopt remote monitoring technologies.

Integration with smartphones, cloud platforms, and wearable ecosystems is enabling real-time health data tracking and proactive intervention, improving outcomes while reducing care costs. Advances in wireless communication, AI-based analytics, and digital therapeutics are creating a robust ecosystem that supports predictive, personalized healthcare at home. Furthermore, global health crises like COVID-19 have accelerated the normalization of self-monitoring, highlighting its role in managing infectious and chronic conditions alike. These combined forces are driving the sustained growth and technological evolution of the homecare self-monitoring devices market.

SCOPE OF STUDY:

The report analyzes the Homecare Self-Monitoring Devices market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Blood Pressure Monitors, Blood Glucose Monitors, SPO2 Monitoring Kit, ECG Machines, Sleep Testing Device, Other Types); Device Type (Wearable, Handheld, Other Device Types); Application (Metabolic Disorders, Circulatory Disorders, Respiratory Track Disorder, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â